Q-omics provides the consensus-scored TOPORSLP profile across patient tissues and cancer cell-line models. TOPORSLP expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TOPORSLP is differentially expressed in 4, with the highest sampling consensus in KIRC. Additionally, TOPORSLP RNA expression shows 6,403 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRC, and STAD as cancer lineages where TOPORSLP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TOPORSLP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TOPORSLP survival associations across molecular data types. TOPORSLP RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TOPORSLP RNA expression–survival associations across cancer types. High TOPORSLP expression shows unfavorable associations in KIRC, READ, MESO, THCA and SARC, but favorable associations in BLCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TOPORSLP RNA expression.
This table summarizes TOPORSLP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TOPORSLP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TOPORSLP shows lower tumor expression in THCA and higher tumor expression in KIRC, LUSC and LIHC. The KIRC box plot shows higher TOPORSLP RNA expression in tumor versus normal tissue (log2 FC = +0.004, t-test p = .026).
This table shows molecular features associated with TOPORSLP in patient tissues and cancer cell lines. In patient samples, TOPORSLP shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
